Abstract
Purpose
Several efforts are being undertaken toward MRI-based treatment planning for ocular proton therapy for uveal melanoma (UM). The interobserver variability of the gross target volume (GTV) on magnetic resonance imaging (MRI) is one of the important parameters to design safety margins for a reliable treatment. Therefore, this study assessed the interobserver variation in GTV delineation of UM on MRI.
Methods and Materials
Six observers delineated the GTV in 10 different patients using the Big Brother contouring software. Patients were scanned at 3T MRI with a surface coil, and tumors were delineated separately on contrast enhanced 3DT1 (T1gd) and 3DT2-weighted scans with an isotropic acquisition resolution of 0.8 mm. Volume difference and overall local variation (median standard deviation of the distance between the delineated contours and the median contour) were analyzed for each GTV. Additionally, the local variation was analyzed for 4 interfaces: sclera, vitreous, retinal detachment, and tumor-choroid interface.
Results
The average GTV was significantly larger on T1gd (0.57cm3) compared with T2 (0.51cm3, P = .01). A not significant higher interobserver variation was found on T1gd (0.41 mm) compared with T2 (0.35 mm). The largest variations were found at the tumor-choroid interface due to peritumoral enhancement (T1gd, 0.62 mm; T2, 0.52 mm). As a result, a larger part of this tumor-choroid interface appeared to be included on T1gd-based GTVs compared with T2, explaining the smaller volumes on T2.
Conclusions
The interobserver variation of 0.4 mm on MRI are low with respect to the voxel size of 0.8 mm, enabling small treatment margins. We recommend delineation based on the T1gd-weighted scans, as choroidal tumor extensions might be missed.
Introduction
Uveal melanoma (UM) arises from melanocytes and is the most common primary intraocular tumor, occurring at a rate of approximately 14 cases per million person-years.
1- Singh AD
- Turell ME
- Topham AK.
Uveal melanoma: Trends in incidence, treatment, and survival.
, With the increased availability of proton beam therapy (PT), the number of patients treated with ocular PT are rising.
3- Hrbacek J
- Mishra KK
- Kacperek A
- et al.
Practice patterns analysis of ocular proton therapy centers: The international OPTIC survey.
Currently, gross target volume (GTV) definition in PT planning for UM is based on a generic model of the eye and tumor, constructed using marker positions and 2-dimensional imaging such as fundus photographs and ocular ultrasound.
4- Aziz S
- Taylor A
- McConnachie A
- Kacperek A
- Kemp E.
Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland.
,5- Sikuade MJ
- Salvi S
- Rundle PA
- Errington DG
- Kacperek A
- Rennie IG.
Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma.
This distinct difference compared with other tumor sites, where computed tomography (CT) and magnetic resonance imaging (MRI) are commonly fused for target and organ-at-risk (OAR) delineation,
6- Das IJ
- McGee KP
- Tyagi N
- Wang H.
Role and future of MRI in radiation oncology.
,7- Yazici G
- Kiratli H
- Ozyigit G
- et al.
Stereotactic radiosurgery and fractionated stereotactic radiation therapy for the treatment of uveal melanoma.
is primarily the result of the poor image quality that could be obtained with conventional ocular MRI techniques. As a result, currently a generic model is used, which has a limited possibility to account for variations in tumor and globe shape. However, over the last decade, eye-specific MRI protocols have resolved the historically poor image quality of ocular MRIs, resulting in increased use of MRI in ocular oncology.
8- Niendorf T
- Beenakker J-WM
- Langner S
- et al.
Ophthalmic magnetic resonance imaging: Where are we (heading to)?.
,9- Beenakker J-WM
- Brouwer NJ
- Chau C
- et al.
Outcome measures of new technologies in uveal melanoma: Review from the european vision institute special interest focus group meeting.
Although some centers incorporate CT- or MRI-based measurements in the tumor and eye model,
10- Foti PV
- Travali M
- Farina R
- et al.
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: Treatment indications and complications.
, 11Jaarsma-Coes MG, Ferreira TA, Marinkovic M, et al. Comparison of MRI-based and conventional measurements for proton beam therapy of uveal melanoma. [e-pub ahead of print]. Ophthalmol Retin. https://doi.org/10.1016/j.oret.2022.06.019, accessed 09 January 2023.
, 12- Denker A
- Cordini D
- Heufelder J
- et al.
Ion accelerator applications in medicine and cultural heritage.
full 3-dimensional (3D) imaging-based GTV definition is currently not commonly used in ocular radiation therapy.
MRI-based tumor and OAR definition could be valuable for ocular PT as its excellent soft tissue contrast and a 3D representation of the tumor and organs at risk
8- Niendorf T
- Beenakker J-WM
- Langner S
- et al.
Ophthalmic magnetic resonance imaging: Where are we (heading to)?.
,13- Ferreira TA
- Fonk LG
- Jaarsma-Coes MG
- van Haren GGR
- Marinkovic M
- Beenakker J-WM.
MRI of uveal melanoma.
,14- Beenakker J-WM
- Jaarsma-Coes MG
- Verbist BM
- et al.
MR-based clip-tumor measurements for proton beam therapy planning of uveal melanoma patients.
could help reduce the target volume and field size, potentially reducing toxicities.
15- Marnitz S
- Cordini D
- Bendl R
- et al.
Proton therapy of uveal melanomas: Intercomparison of MRI-based and conventional treatment planning.
Therefore, several efforts are being undertaken to enable a fully MRI-based treatment planning for ocular PT as it would allow for a more patient-specific geometric description of the tumor and OAR than the currently used model-based approach.
15- Marnitz S
- Cordini D
- Bendl R
- et al.
Proton therapy of uveal melanomas: Intercomparison of MRI-based and conventional treatment planning.
, 16- Fleury E
- Trnková P
- Erdal E
- et al.
Three-dimensional MRI-based treatment planning approach for non-invasive ocular proton therapy.
, 17- Hassan MK
- Fleury E
- Shamonin D
- et al.
An automatic framework to create patient-specific eye models from 3D MR-images for treatment selection in patients with uveal melanoma.
, 18- Pfeiffer K
- Dobler B
- Rethfeldt C
- Schlegel W
- Bendl R.
OCTOPUS: A planning tool for proton therapy of eye tumours.
, 19- Nguyen HG
- Sznitman R
- Maeder P
- et al.
Personalized anatomic eye model from T1-weighted volume interpolated gradient echo magnetic resonance imaging of patients with uveal melanoma.
, 20- Nguyen H-G
- Pica A
- Hrbacek J
- et al.
A novel segmentation framework for uveal melanoma in magnetic resonance imaging based on class activation maps.
, 21- Via R
- Hennings F
- Pica A
- et al.
Potential and pitfalls of 1.5T MRI imaging for target volume definition in ocular proton therapy.
As delineation variability is an important source of uncertainty in radiation therapy, it contributes to a significant portion of the treatment margins.
22Errors and margins in radiotherapy.
,23- Rasch C
- Steenbakkers R
- van Herk M.
Target definition in prostate, head, and neck.
For ocular MRI, however, this variation is currently unknown and, because of the eye's small size and eye-specific imaging challenges such as eye-blink artefacts,
24- Berkowitz BA
- McDonald C
- Ito Y
- Tofts PS
- Latif Z
- Gross J.
Measuring the human retinal oxygenation response to a hyperoxic challenge using MRI: Eliminating blinking artifacts and demonstrating proof of concept.
,25- Wezel J
- Garpebring A
- Webb AG
- van Osch MJP
- Beenakker J-WM.
Automated eye blink detection and correction method for clinical MR eye imaging.
results from other anatomies cannot be translated to the eyes. Therefore, the aim of this study is to assess the interobserver variation on GTV delineation of UM on MRI.
Discussion
We found in general an interobserver variation of 0.4 mm, which is essential information for the determination of the margin for MRI-based radiation therapy planning of intraocular tumors. This variation in significantly smaller than for other malignancies, such as pancreatic, prostate, and recurrent gynecological cancer, where observer variations in the order of 2 to 10 mm are commonly found.
30- Gurney-Champion OJ
- Versteijne E
- van der Horst A
- et al.
Addition of MRI for CT-based pancreatic tumor delineation: A feasibility study.
, 31- Versteijne E
- Gurney-Champion OJ
- van der Horst A
- et al.
Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: A multi-institutional study.
, 32- Machiels M
- Jin P
- van Hooft JE
- et al.
Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers.
, 33- Steenbergen P
- Haustermans K
- Lerut E
- et al.
Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation.
, 34- Rasch CRN
- Steenbakkers RJHM
- Fitton I
- et al.
Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer.
, 35- Bernstein D
- Taylor A
- Nill S
- et al.
An inter-observer study to determine radiotherapy planning target volumes for recurrent gynaecological cancer comparing magnetic resonance imaging only with computed tomography-magnetic resonance imaging.
, 36- Steenbakkers R
- Duppen J
- Fitton I
- et al.
A 3D analysis and reduction of observer variation in delineation of lung cancer for radiotherapy.
, 37- Steenbakkers RJHM
- Duppen JC
- Fitton I
- et al.
Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis.
The higher agreement between observers found in this study is likely the result of relatively high resolution of the MRIs, which is also needed for a small target organ, such as the eye.
13- Ferreira TA
- Fonk LG
- Jaarsma-Coes MG
- van Haren GGR
- Marinkovic M
- Beenakker J-WM.
MRI of uveal melanoma.
Potentially this variation can be reduced even further, for instance by improving the delineation instructions based on the results of this study.
The observer variation of 0.4 mm was approximately half of the acquisition voxel size (0.8 mm isotropic) and in line with previous eye segmentation studies showing a segmentation reproducibility of less than 1 voxel.
38- Jaarsma-Coes MG
- Marinkovic M
- Astreinidou E
- et al.
Measuring eye deformation between planning and proton beam therapy position using magnetic resonance imaging.
,39- Beenakker J-WM
- Shamonin DP
- Webb AG
- Luyten GPM
- Stoel BC.
Automated retinal topographic maps measured with magnetic resonance imaging.
Even the 95th percentile of the local SD is well within the 2.5-mm margin which is commonly used for ocular PT planning worldwide.
40- Damato B
- Kacperek A
- Chopra M
- Campbell IR
- Errington RD.
Proton beam radiotherapy of choroidal melanoma: The Liverpool-Clatterbridge experience.
, 41Proton therapy for the management of uveal melanoma and other ocular tumors.
, 42- Dendale R
- Lumbroso-Le Rouic L
- Noel G
- et al.
Proton beam radiotherapy for uveal melanoma: Results of Curie Institut-Orsay Proton Therapy Center (ICPO).
, 43Protontherapy of eye tumours in the UK: A review of treatment at Clatterbridge.
, 44- Egger E
- Zografos L
- Schalenbourg A
- et al.
Eye retention after proton beam radiotherapy for uveal melanoma.
, 45- Caujolle J-P
- Paoli V
- Chamorey E
- et al.
Local recurrence after uveal melanoma proton beam therapy: Recurrence types and prognostic consequences.
, 46- Sas-Korczyńska B
- Markiewicz A
- Romanowska-Dixon B
- Pluta E.
Preliminary results of proton radiotherapy for choroidal melanoma - the Kraków experience.
, 47- Seibel I
- Cordini D
- Rehak M
- et al.
Local recurrence after primary proton beam therapy in uveal melanoma: Risk factors, retreatment approaches, and outcome.
In addition to the uncertainties in the model based tumor definition, this margin is used to account for the variation in patient set up between fractions, movement of the eye during treatment, and beam characteristics.
41Proton therapy for the management of uveal melanoma and other ocular tumors.
As no prior publications were found on the observer variation of the GTV delineation in UM on high resolution MRI scans, the observer variation was compared with uncertainties in conventional measurements for ocular PT planning. Currently GTV definition of conventional ocular PT planning is based on the distance between tumor and tantalum markers in combination with tumor prominence and largest basal diameter measurements on ultrasound and fundoscopy. Studies demonstrated an observer variation (SD) with B-scan ultrasonography for prominence measurement of 0.6 mm
48- Char DH
- Kroll S
- Stone RD
- Harrie R
- Kerman B.
Ultrasonographic measurement of uveal melanoma thickness: Interobserver variability.
and 0.7 mm for the tumor base.
49- Haritoglou C
- Neubauer AS
- Herzum H
- Freeman WR
- Mueller AJ.
Interobserver and intraobserver variability of measurements of uveal melanomas using standardised echography.
Furthermore, fundoscopic images are optically deformed and differ on average 1.2 mm from ultrasound measurements of the largest basal diameter.
50- Pe'er JJ
- Sancho C
- Cantu J
- et al.
Measuring choroidal melanoma basal diameter: Using ultrasound vs. a new wide–angle fundus camera.
Even though these uncertainties and variations are not directly comparable as they involve different types of measures, it indicates that the observer variation observed on MRI might be similar or smaller than the current standard. Comparison with CT, which is commonly used for ocular stereotactic radiosurgery,
51Radiation therapy for uveal melanoma: A review of treatment methods available in 2021.
was not possible as no literature was found on the observer variation of intraocular GTV delineation with CT.
We showed that the observer variation depends on the type of tissue adjacent to the tumor, with the lowest variation at the tumor-vitreous interface. The highest variation was observed at the tumor-choroid interface, especially on T1gd as there was no agreement on whether choroidal enhancement should be included in the GTV. Although more clear instructions on whether or not to consider this choroidal enhancement as tumor will likely reduce the observer variation, it is more important to know if this enhancement contains tumor cells. Unfortunately, no histopathologic validation was found in the literature. On T2, the choroidal enhancing area is generally hyperintense compared with the tumor and isointense compared with vitreous and was therefore not included in the GTV. This is the primary source of the volume differences between T1gd and T2 segmented GTVs. Out of concern for choroidal microinvasion, we recommend including choroidal enhancement in the GTV until proven otherwise by histopathology. Clarity about the etiology of enhancement and reduction of the observer variability around the tumor edge is most important for tumors located in close proximity of OARs such as macula and optic nerve. This is also relevant for application of MRI-based tumor models outside ocular PT such as treatment decision making, brachytherapy planning, or follow-up after treatment. Especially for brachytherapy, where the base of the tumor determines the size of the brachytherapy applicator, it is important to have an accurate and reliable determination of the tumor base. Additionally, fundus imaging can be used for verification of the tumor base. However, it should be noted that optical aberrations and mismatches in the fusion are potential additional sources of errors.
50- Pe'er JJ
- Sancho C
- Cantu J
- et al.
Measuring choroidal melanoma basal diameter: Using ultrasound vs. a new wide–angle fundus camera.
Nevertheless, a combined evaluation for treatment planning is certainly advised, especially for flat UM.
11Jaarsma-Coes MG, Ferreira TA, Marinkovic M, et al. Comparison of MRI-based and conventional measurements for proton beam therapy of uveal melanoma. [e-pub ahead of print]. Ophthalmol Retin. https://doi.org/10.1016/j.oret.2022.06.019, accessed 09 January 2023.
Unexpectedly, no difference in interobserver variability was found between T1gd and T2 at the retinal detachment interface. This might be due to the limited sample size, especially of the patients with retinal detachment. However, inclusion of a small retinal detachment on T2-weighted images in patient 8 most likely led to overestimation of tumor volume. Additionally, in rare cases, a hemorrhagic retinal detachment can be difficult to distinguish from tumor when only using T1gd weighted images.
10- Foti PV
- Travali M
- Farina R
- et al.
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging-Part II: Treatment indications and complications.
This underlines the importance of the use of high-resolution scans and comparison of different MRI sequences for tissue characterization, as it allows for an accurate discrimination between both components.
52- Foti PV
- Travali M
- Farina R
- et al.
Diagnostic methods and therapeutic options of uveal melanoma with emphasis on MR imaging—Part I: MR imaging with pathologic correlation and technical considerations.
Compared with the tumor-choroid interface and retinal detachment, the base of the tumor had a relatively low observer variation. Nonetheless, enhancing muscle insertions might result in increased variation locally when mistaken for tumor. Finally, extra care should also be taken in case of flat UM or tumors with flat extensions as these can be missed on MRI.
14- Beenakker J-WM
- Jaarsma-Coes MG
- Verbist BM
- et al.
MR-based clip-tumor measurements for proton beam therapy planning of uveal melanoma patients.
Even though T2 has a slightly, not significant, lower observer variation compared with T1gd, we recommend delineation on T1gd as enhancement might represent tumor invasion which might be missed on T2. Moreover, differentiation between tumor and retinal detachment might be more difficult on T2. However, to achieve the most accurate GTV delineation, it is important to use the multiple scan sequences for tissue differentiation and to choose the least affected sequence in case of motion artifacts. The determined observer variation aids in establishing the margin for MRI-based ocular PT treatment planning. Furthermore, the regional SD differences might lead to different treatment beam design strategies by, for example, preferring the major axis of the tumor to be in the anterior-posterior direction. Outside PT, MRI-based tumor models might be used for treatment decision making, brachytherapy planning, and follow-up after treatment.
Although this study assessed the observer variation for MRI alone, in clinical practice, the strengths of different modalities will be combined to determine the GTV. Therefore, the final variation will depend on the variation of each of these modalities and on how accurately these can be combined. To prevent the confounding effect of errors in the registration of different modalities, for example, fundus photography and MRI, we based these results on MRI-data alone and used the median GTV as a ground truth, similar to other studies.
30- Gurney-Champion OJ
- Versteijne E
- van der Horst A
- et al.
Addition of MRI for CT-based pancreatic tumor delineation: A feasibility study.
, 31- Versteijne E
- Gurney-Champion OJ
- van der Horst A
- et al.
Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: A multi-institutional study.
, 32- Machiels M
- Jin P
- van Hooft JE
- et al.
Reduced inter-observer and intra-observer delineation variation in esophageal cancer radiotherapy by use of fiducial markers.
, 33- Steenbergen P
- Haustermans K
- Lerut E
- et al.
Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation.
, 34- Rasch CRN
- Steenbakkers RJHM
- Fitton I
- et al.
Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer.
, 35- Bernstein D
- Taylor A
- Nill S
- et al.
An inter-observer study to determine radiotherapy planning target volumes for recurrent gynaecological cancer comparing magnetic resonance imaging only with computed tomography-magnetic resonance imaging.
, 36- Steenbakkers R
- Duppen J
- Fitton I
- et al.
A 3D analysis and reduction of observer variation in delineation of lung cancer for radiotherapy.
, 37- Steenbakkers RJHM
- Duppen JC
- Fitton I
- et al.
Reduction of observer variation using matched CT-PET for lung cancer delineation: A three-dimensional analysis.
However, to use this information in clinical practice, it would be valuable to also determine the uncertainties in the other steps in ocular proton therapy, for example, variation in patient setup, so a more modern margin recipe for ocular PT can be developed instead of the currently used gross margin of 2.5 mm.
40- Damato B
- Kacperek A
- Chopra M
- Campbell IR
- Errington RD.
Proton beam radiotherapy of choroidal melanoma: The Liverpool-Clatterbridge experience.
, 41Proton therapy for the management of uveal melanoma and other ocular tumors.
, 42- Dendale R
- Lumbroso-Le Rouic L
- Noel G
- et al.
Proton beam radiotherapy for uveal melanoma: Results of Curie Institut-Orsay Proton Therapy Center (ICPO).
, 43Protontherapy of eye tumours in the UK: A review of treatment at Clatterbridge.
, 44- Egger E
- Zografos L
- Schalenbourg A
- et al.
Eye retention after proton beam radiotherapy for uveal melanoma.
, 45- Caujolle J-P
- Paoli V
- Chamorey E
- et al.
Local recurrence after uveal melanoma proton beam therapy: Recurrence types and prognostic consequences.
, 46- Sas-Korczyńska B
- Markiewicz A
- Romanowska-Dixon B
- Pluta E.
Preliminary results of proton radiotherapy for choroidal melanoma - the Kraków experience.
, 47- Seibel I
- Cordini D
- Rehak M
- et al.
Local recurrence after primary proton beam therapy in uveal melanoma: Risk factors, retreatment approaches, and outcome.
In this context, a study on the use of MRI to define the OAR would also be relevant, as their location and extend are currently approximated. Finally, although the results of this study contribute to a marker less GTV definition in ocular PT, in the current praxis, markers will still be required for the accurate positioning the tumor with respect to the proton beam.
Article info
Publication history
Published online: December 23, 2022
Accepted:
December 14,
2022
Received:
June 16,
2022
Footnotes
Sources of support: This work was supported by the Netherlands Organization for Scientific Research (NWO) [protons4vision 14654].
Disclosures: We received research support from Philips Health care. They had no role in the design of the study; in the collection, analyses, nor interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.
The data sets generated during the study are not publicly available as they contains potentially identifying information. The data are available from the corresponding author on reasonable request and after the signing of a data transfer agreement.
Copyright
© 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.